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 Introduction 
 Almost two decades ago, it was found that a group of 
chemotactic cytokines specifically triggers the migration 
of leukocytes  [1] . The expanding numbers of  chemokines 
and their complex interactions with chemokine receptors 
(both referred to as chemokine mediators in this review) 
set off broad research activities in all areas of medicine. 
Meanwhile, industry has taken over to develop chemo-
kine antagonism as a novel therapeutic concept for in-
flammatory diseases. While clinical trials with chemo-
kine and chemokine receptor antagonists are ongoing  [2] , 
research in the field of chemokine biology remains an 
area of unexpected discoveries. This review raises and 
discusses a number of open questions that may help to 
plan and interpret chemokine research in the context of 
renal inflammation.
 Does Renal Expression of Chemokine Mediators 
Predict Functional Significance? 
 The rationale to block chemokines or chemokine re-
ceptors in renal inflammation is usually based on data 
demonstrating their expression in human renal biopsies 
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 Abstract 
 Chemokines remain attractive therapeutic targets for mod-
ulating inflammatory diseases in all areas of medicine in-
cluding acute and chronic kidney disease. Industry has 
launched huge programs for the development of chemo-
kine antagonists, and clinical trials with chemokine and che-
mokine receptor antagonists are ongoing. However, chemo-
kine biology remains an area of unexpected discoveries. 
Here we discuss a number of questions which need to be ad-
dressed to further explore the potential of chemokine an-
tagonism in renal inflammation: Why does renal expression 
of chemokines and chemokine receptors not always corre-
late with their functional significance? Why does chemokine 
antagonism only partially reduce renal leukocyte counts? 
Will antagonist combinations be more effective in reducing 
renal inflammation? What are the functional roles of homeo-
static chemokines and atypical, nonsignaling chemokine re-
ceptors in renal inflammation? And finally, what classes of 
chemokine antagonists are available to address these ques-
tions experimentally?  Copyright © 2009 S. Karger AG, Basel 
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or along the progression of experimental kidney disease 
in rodents. For example, the monocyte chemoattractant 
protein (MCP)-1/CCL2 has consistently been shown to 
be secreted by proximal tubular epithelial cells of pro-
teinuric mice, rats and humans  [3] . These observations 
correlated with chemokine receptor CCR2+ macrophage 
and T cell infiltrates in adjacent interstitial areas. As 
such, it was predicted that the known function of MCP-
1/CCL2 to trigger the recruitment of CCR2+ macro-
phages and T cells in in vitro assays would translate
to experimental renal inflammation, a prediction con-
firmed by numerous interventional studies in rodents  [3, 
4] . CCR5 is also present on monocytes and T cells and 
was shown to specifically mediate leukocyte spreading 
in flow chamber experiments. Thus, it was predicted that 
CCR5 would also contribute to the renal recruitment of 
CCR5+ macrophages and T cells. However, interstitial 
macrophage and T cell recruitment turned out to be in-
dependent of CCR5, at least in mice with renal intersti-
tial fibrosis  [5] . In addition, two CCR5 antagonists, AOP-
RANTES and Met-RANTES, did not affect interstitial 
leukocyte recruitment in the same model (own unpubl. 
data). Moreover, lack of CCR5 rather increased intersti-
tial leukocyte numbers and renal injury in murine cres-
centic glomerulonephritis via increased expression of 
CCL3 and CCL5  [6] . These two CC chemokines mediate 
the recruitment of T cells via CCR1, as such CCR1-defi-
cient mice show altered macrophage and T cell recruit-
ment into the tubulointerstitial compartment after uni-
lateral ureteral obstruction  [5] or in crescentic glomeru-
lonephritis  [7] . Hence, expression studies may suggest, 
but not always predict the functional role of chemokine 
mediators in experimental renal inflammation. A pos-
sible explanation for this phenomenon is that multiple 
chemokine receptors are present on the surface of in-
filtrating leukocytes and some of them may shuttle
passively into the kidney without being functionally in-
volved in the recruitment process. Still, they will be
detectable by descriptional expression studies, e.g. tran-
scriptome analysis or immunostaining. Wheth er a sin-
gle molecule has a functional role for recruitment or not 
can only be answered by blocking the function of the 
factor of interest, e.g. by appropriate antagonists. In or-
der to obtain reliable results, it is necessary that such 
compounds have sufficient species specificity, selective-
ly inhibit the target molecule, and are administered at an 
appropriate dose based on compound-specific pharma-
cokinetics and pharmacodynamics in the species stud-
ied  [8] .
 Why Does Chemokine Antagonism Only Partially 
Reduce Renal Leukocyte Counts? 
 Although considerable redundancy of single chemo-
kine mediators was initially suspected, many interven-
tional studies revealed that specific antagonists of single 
chemokine mediators can have significant effects on leu-
kocyte recruitment to diseased tissues. Such data sup-
ported the concept that at least some mediators have pre-
dominant roles in certain disease entities. On the other 
hand, data from different groups using various method-
ological approaches documented that blocking a single 
chemokine mediator never entirely abrogated leukocyte 
recruitment. For example, MCP-1/CCL2 or CCR2 block-
ade both reduced glomerular or interstitial macrophage 
numbers by approximately 50%, no matter what dose or 
treatment duration was applied  [3, 4] . Three potential 
explanations have been discussed: (1) redundancy of sin-
gle chemokine mediators, (2) local leukocyte prolifera-
tion which affects tissue leukocyte numbers indepen-
dent of influx of circulating cells, and (3) variable leuko-
cyte phenotypes with variable expression patterns of 
chemokine receptors. It is now becoming clear that prob-
ably all three mechanisms limit the ability of chemokine 
antagonism to reduce tissue leukocyte numbers near to 
zero. Especially the evolving concept of macrophage het-
erogeneity and phenotypic flexibility in changing cyto-
kine microenvironments offers fascinating perspectives 
either to explain the aforementioned phenomenon or to 
learn more about how to specifically modulate renal in-
flammation  [9] . For example, classically activated mac-
rophages of a proinflammatory phenotype express CCR2 
on the surface, and alternatively activated macrophages 
with a wound-healing anti-inflammatory capacity lack 
CCR2 expression. In this regard, MCP-1/CCL2 and 
CCR2 blockade may selectively inhibit the influx of 
monocytes with a predominant proinflammatory phe-
notype, and may not affect those macrophage pheno-
types with predominant immunoregulatory or anti-in-
flammatory functions. In addition, leukocytes with anti-
inflammatory properties also recruit to the kidney, e.g. 
NKT cells  [10] and regulatory T cells  [11] . Blocking the 
recruitment of these cells may also explain unexpected 
outcomes of renal disease models in chemokine receptor 
knockout mice or mice treated with chemokine antago-
nists  [6, 7, 10] .
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 Will Antagonist Combinations More Effectively 
Reduce Renal Inflammation? 
 The aforementioned concept would suggest that strat-
egies targeting two or more chemokines attracting iden-
tical leukocyte subsets may not necessarily elicit additive 
effects on leukocyte counts or tissue damage. The same 
would apply for chemokine receptors that are coex-
pressed by the same cell type and share redundant func-
tions. Some of our own unpublished data seem to sup-
port this hypothesis. Simultaneous blockade of CCR2 
and CCR5 was not superior to MCP-1/CCL2 inhibition 
in terms of reducing glomerular macrophage counts and 
glomerular scaring in a murine model of glomeruloscle-
rosis. In contrast, combined chemokine antagonism may 
be more likely to have additive effects on tissue damage 
when different disease pathomechanisms are targeted. 
In view of the suspected role of regulatory and wound-
healing macrophage phenotypes for the progression of 
chronic glomerulopathies and interstitial fibrosis, it will 
become very important to identify the chemokines that 
mediate recruitment of these macrophage subclasses 
into the kidney. Thus, antagonist combinations that si-
multaneously prevent the recruitment of proinflamma-
tory as well as profibrotic leukocyte subsets have the po-
tential for additive therapeutic effects. It may also be
important to develop different strategies for acute or 
chronic renal inflammation as wound-healing leuko-
cyte phenotypes may either support the resolution of
renal inflammation, e.g. in the healing phase of acute 
tubular necrosis  [12] , or facilitate interstitial fibrosis in 
chronic kidney disease.
 What Are the Roles of Homeostatic Chemokines in 
the Kidney? 
 Not much is known about the roles of the homeo-
static chemokines in the kidney because these are 
thought to mainly orchestrate the migration to and the 
spatial distribution within lymphoid organs and bone 
marrow. For example, B cell-attracting chemokine-1/
CXCL13 and its receptor CXCR5, physiologically or-
chestrating B cell homing in lymph nodes, is also asso-
ciated with renal B cell infiltrates and clusters in lupus 
nephritis and renal vasculitis  [13] . As another example, 
stromal cell-derived factor (SDF)-1/CXCL12 mediates 
stem cell-homing in the bone marrow but also recruits 
mesenchymal progenitor cells to the postischemic kid-
ney  [14] . CXCR4 blockade can also prevent chronic lu-
pus-like glomerulonephritis in MRLlpr mice, but the 
contribution of intrarenal SDF-1/CXCR12 expression in 
this model remains unclear  [15] . We have recently dis-
covered that glomerular SDF-1/CXCL12 expression de-
rives from podocytes in db/db mice with type 2 diabetes 
and that SDF-1/CXCL12 antagonism can prevent dia-
betic glomerulosclerosis without affecting glomerular 
leukocyte numbers  [16] . Such data indicate that as yet 
unknown functions of chemokines remain to be discov-
ered and that these may reveal novel pathomechanisms 
and therapeutic targets in kidney disease. To further ex-
tend the aforementioned concept of chemokine co-
blockade, it might be more effective to simultaneously 
target proinflammatory and homeostatic chemokines 
rather than different members of the same group. How-
ever, experimental data to support this hypothesis are 
not yet available in the public domain.
 What Are the Roles of Atypical, Nonsignaling 
Chemokine Receptors? 
 Some ‘atypical’ chemokine receptors do not mediate 
intracellular calcium ion mobilization upon binding of 
their chemokine ligands, i.e. the Duffy antigen/receptor 
of chemokines (DARC), D6, the chemocentryx chemo-
kine receptor (CCX-CKR), and CXCR7  [17] . The atypical 
receptors share alterations in the canonical DRYLAIF 
motif which mediates G-protein coupling in all other 
chemokine receptors. DARC binds several inflammatory 
CC and CXC chemokines, D6 binds to almost all pro-
inflammatory and homeostatic CC chemokines, CCX-
CKR binds the homeostatic chemokines ELC/CCL19, 
SLC/CCL21, and TECK/CCL25, and CXCR7 binds I-
TAC/CXCL11 and SDF-1/CXCL12  [17, 18] . There is 
emerging evidence that atypical chemokine receptors 
regulate chemokine functions, e.g. by binding, internal-
ization and intracellular degradation like other function-
al decoys and scavenger receptors. Dependent on their 
cell-, organ- and context-specific expression, the atypical 
receptors can negatively regulate chemokine signals, and 
hence, control bioavailable chemokine levels in a particu-
lar microenvironment to influence the recruitment of in-
flammatory cells to that site. Current experimental data 
suggest that D6, CCX-CKR, and CXCR7 act as scaven-
gers for their respective ligands, with D6 mainly reducing 
local levels of inflammatory chemokines, and CCX-CKR 
regulating homeostatic chemokine concentrations  [18] . 
DARC internalizes chemokines from the basolateral cell 
surface of vascular endothelial cells. Interestingly, this 
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does not lead to degradation, but DARC mediates chemo-
kine transcytosis, leading to increased apical retention of 
intact chemokines, increased presentation of these che-
mokines to leukocytes and enhanced leukocyte migra-
tion across monolayers  [19] . Together with the known ex-
pression of DARC on high endothelial venules of lymph 
nodes and postcapillary venules, i.e. sites of leukocyte ex-
travasation, these data suggest that DARC internalizes 
and transports tissue-derived inflammatory chemokines 
onto the luminal endothelial cell surface where they en-
hance local leukocyte recruitment. In inflamed kidneys, 
expression of DARC is induced in interstitial endothelial 
cells. Consistently, DARC deficiency ameliorated disease 
in two neutrophil-dependent models of acute renal in-
jury  [20] . However, in renal disease models with a pre-
dominant infiltration of renal macrophages and T cells, 
DARC deficiency did not improve renal inflammation. 
In contrast, renal leukocyte infiltrates were increased in 
DARC-deficient mice at early time points, accelerating 
renal injury without affecting outcomes in the later dis-
ease phase  [21] . These results suggest that DARC ex-
pressed on interstitial endothelial cells contributes to re-
nal neutrophil recruitment, but its role is redundant for 
the infiltration of macrophages and T cells. Nevertheless, 
Table 1. Chemokine receptor antagonists in clinical trials 
Target Company Compound name Trial phase Indication Comments
CCR1 Berlex Biosciences BX-471 (ZK-811752) II MS, psoriasis, endometriosis no longer reported
Millennium/Aventis MLN-3897 II RA, MS no efficacy in RA
ChemoCentryx CCX354 I RA ongoing
Pharmacopeia PS-031291 IIa myeloma, RA ongoing
Pfizer CP-481,715 II RA no efficacy
Millennium MLN-3701 I RA, MS ongoing
CCR2 Millennium Pharmaceuticals MLN-1202 (antibody) II atherosclerosis, MS, RA no efficacy for RA, others ongoing 
Incyte Pharmaceuticals INCB8696 I MS, SLE ongoing
ChemoCentryx CCX140 I MS, restenosis ongoing
Merck MK-0812 II RA, MS no efficacy
Pfizer PF-4136309 II pain ongoing
CCR3 Cambridge
AT/Vancouver Biotech
CAT-213
(antibody, bertilimumab)
II ocular allergies,
allergic conjunctivitis
ongoing
Topigen TPIASM8 II asthma ongoing
GlaxoSmithKline GW-766994 II asthma, allergic rhinitis no longer reported
Bristol-Myers Squibb DPC-168 I asthma no longer reported
CCR4 Amgen KW-0761 I oncology ongoing
CCR5 Pfizer Maraviroc (UK-427857) approved HIV approved
II RA ongoing
Schering-Plough Vicriviroc (Sch-417690) II HIV ongoing
GlaxoSmithKline Aplaviroc III HIV toxicity reported
Incyte INCB9471 II HIV ongoing
Progenics Pro 140 I HIV ongoing
Schering-Plough Sch-351125 I COPD ongoing
Ono Pharm. GlaxoSmithKline ONO-4128 II HIV terminated because of liver toxicity
CXCR1/2 Schering-Plough SCH 527123 II COPD ongoing
Dompe Reparixin II reperfusion injury ongoing
GlaxoSmithKline SB-656933 I COPD, cystic fibrosis ongoing
CXCR3 Amgen/Tularik T-487/AMG-487 II psoriasis no efficacy, trials halted
CXCR4 Genzyme/AnorMED Plerixafor (AMD-3100) approved stem cell transplantation approved
III multiple myeloma ongoing
AnorMED AMD-070 II HIV ongoing
Chemokine Therapeutics CTCE-0214 II stem cell transplantation ongoing
Modified from Horuk [2]. MS = Multiple sclerosis; RA = rheumatoid arthritis; COPD = chronic obstructive pulmonary disease; SLE = systemic lupus 
erythematosus.
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specific antagonism of DARC on endothelial cells (e.g. by 
antisense approaches) emerges as a potential therapeutic 
strategy especially in acute renal inflammation. In con-
trast, soluble DARC-IgG fusion proteins may have a po-
tential therapeutic effect similar to the suggested sink 
function of erythrocyte-expressed DARC. To date, it is 
unknown whether the other atypical chemokine recep-
tors D6, CCX-CKR, and CXCR7 are directly involved
in downregulating inflammatory responses in acute or 
chronic renal injury. 
 What Classes of Chemokine Antagonists Are 
Available?  
 In the early days of chemokine research, antagonists 
were generated by different technical approaches like 
neutralizing antibodies to chemokines and chemokine 
receptors as well as truncated, mutated or modified che-
mokine proteins. Some chemokine receptor antibodies 
or modified chemokines were found to elicit partial ago-
nistic effects which compromised the interpretation of 
the data. Although most companies favored the develop-
ment of small molecule receptor antagonists, neutraliz-
ing antibodies are among those compounds currently 
tested in clinical trials ( table 1 ). Other technologies like 
small peptide-based receptor inhibitors or RNAse-resis-
tant RNA aptamers are still in preclinical development. 
Meanwhile, chemokine receptor antagonists blocking 
CCR5 or CXCR4 have been approved for therapy in hu-
man HIV infection and stem cell transplantation, respec-
tively ( table 1 ). Their lack of efficacy, e.g. in multiple scle-
rosis or rheumatoid arthritis studies, has dampened the 
initial enthusiasm regarding their therapeutic potential 
in chronic inflammatory disease  [2] . This may be a result 
of oversimplifying concepts on chemokine biology in the 
early days. Thus, more research is required to identify ap-
propriate antagonistic strategies to control inflammation 
and tissue remodeling in clearly defined disease contexts. 
The availability of specific antagonists should help ex-
perimental nephrologists, provided that the compounds 
are suitable for the model species from a pharmacody-
namic point of view. 
 Summary and Perspective 
 The role of chemokine mediators in experimental kid-
ney disease remains an attractive research field holding 
the potential for unexpected discoveries in the future. We 
need to identify how specific leukocyte subpopulations 
like immunoregulatory macrophages, B cells, Th17 cells, 
regulatory T cells, and the different types of renal pro-
genitor cells recruit to the different renal compartments 
during the different phases of acute and chronic nephrop-
athies. In addition, we need to learn more about the roles 
of the homoeostatic chemokines and the atypical chemo-
kine receptors in inflammatory renal disease to identify 
new therapeutic strategies based on these molecules. 
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